Plasma copeptin, a unifying factor behind the metabolic syndrome

Journal of Clinical Endocrinology and Metabolism

Volumn 96, Issue 7, 2011, Pages

  Enhörning, Sofia ^a,b   Struck, Joachim ^c   Wirfält, Elisabet ^a   Hedblad, Bo ^a   Morgenthaler, Nils G ^c   Melander, Olle ^a,b  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c THERMO FISHER SCIENTIFIC   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARGIPRESSIN DERIVATIVE; C REACTIVE PROTEIN; COPEPTIN; HIGH DENSITY LIPOPROTEIN; INSULIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ABDOMINAL OBESITY; ADULT; AGE; ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; CIGARETTE SMOKING; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; FAT INTAKE; FEMALE; HUMAN; HYPERTENSION; INSULIN BLOOD LEVEL; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PHYSICAL ACTIVITY; POPULATION RESEARCH; PRIORITY JOURNAL; SEX DIFFERENCE; SOCIAL STATUS; SWEDEN; WAIST CIRCUMFERENCE;

AGED; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; DIETARY FATS; FEMALE; GLYCOPEPTIDES; HUMANS; INSULIN; INSULIN RESISTANCE; LIFE STYLE; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MOTOR ACTIVITY; OBESITY; PROSPECTIVE STUDIES; SOCIAL CLASS; SWEDEN;

EID: 79960087721     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2010-2981     Document Type: Article

References (37)

1. Grundy SM 2008 Metabolic syndrome pandemic. Arterioscler Thromb Vasc Biol 28:629-636 (Pubitemid 351651324)
2. Morel A, O'Carroll AM, Brownstein MJ, Lolait SJ 1992 Molecular cloning and expression of a rat V1a arginine vasopressin receptor. Nature 356:523-526
3. Hiroyama M, Aoyagi T, Fujiwara Y, Birumachi J, Shigematsu Y, Kiwaki K, Tasaki R, Endo F, Tanoue A 2007 Hypermetabolism of fat in V1a vasopressin receptor knockout mice. Mol Endocrinol 21:247-258 (Pubitemid 46041703)
4. Folny V, Raufaste D, Lukovic L, Pouzet B, Rochard P, Pascal M, Serradeil-Le Gal C 2003 Pancreatic vasopressin V1b receptors: characterization in In-R1-G9 cells and localization in human pancreas. Am J Physiol Endocrinol Metab 285:E566-E576 (Pubitemid 37010835)
5. de Keyzer Y, Auzan C, Lenne F, Beldjord C, Thibonnier M, Bertagna X, Clauser E 1994 Cloning and characterization of the human V3 pituitary vasopressin receptor. FEBS Lett 356:215-220
6. Lolait SJ, O'Carroll AM, McBride OW, Konig M, Morel A, Brownstein MJ 1992 Cloning and characterization of a vasopressin V2 receptor and possible link to nephrogenic diabetes insipidus. Nature 357:336-339
7. Filep J, Rosenkranz B 1987 Mechanism of vasopressin-induced platelet aggregation. Thromb Res 45:7-15 (Pubitemid 17006301)
8. Ohlstein EH, Berkowitz BA 1986 Human vascular vasopressin receptors: analysis with selective vasopressin receptor antagonists. J Pharmacol Exp Ther 239:737-741 (Pubitemid 17225841)
9. Struck J, Morgenthaler NG, Bergmann A 2005 Copeptin, a stable peptide derived from the vasopressin precursor, is elevated in serum of sepsis patients. Peptides 26:2500-2504 (Pubitemid 41676723)
10. Enhörning S, Wang TJ, Nilsson PM, Almgren P, Hedblad B, Berglund G, Struck J, Morgenthaler NG, Bergmann A, Lindholm E, Groop L, Lyssenko V, Orho-Melander M, Newton-Cheh C, Melander O 2010 Plasma copeptin and the risk of diabetes mellitus. Circulation 121:2102-2108
11. Saleem U, Khaleghi M, Morgenthaler NG, Bergmann A, Struck J, Mosley Jr TH, Kullo IJ 2009 Plasma carboxy-terminal provasopressin (copeptin): a novel marker of insulin resistance and metabolic syndrome. J Clin Endocrinol Metab 94:2558-2564
12. Pollard AD, Brindley DN 1984 Effects of vasopressin and corticosterone on fatty acid metabolism and on the activities of glycerol phosphate acyltransferase and phosphatidate phosphohydrolase in rat hepatocytes. Biochem J 217:461-469 (Pubitemid 14178976)
13. Zenteno-Savin T, Sada-Ovalle I, Ceballos G, Rubio R 2000 Effects of arginine vasopressin in the heart are mediated by specific intravascular endothelial receptors. Eur J Pharmacol 410:15-23 (Pubitemid 32008126)
14. Allal-Elasmi M, Haj Taieb S, Hsairi M, Zayani Y, Omar S, Sanhaji H, Jemaa R, Feki M, Elati J, Mebazaa A, Kaabachi N 2010 The metabolic syndrome: prevalence, main characteristics and association with socio-economic status in adults living in Great Tunis. Diabetes Metab 36:204-208
15. Masulli M, Riccardi G, Galasso R, Vaccaro O 2006 Relationship between smoking habits and the features of the metabolic syndrome in a non-diabetic population. Nutr Metab Cardiovasc Dis 16:364-370
16. Misra KB, Endemann SW, Ayer M 2005 Leisure time physical activity and metabolic syndrome in Asian Indian immigrants residing in northern California. Ethn Dis 15:627-634 (Pubitemid 41645130)
17. Baik I, Shin C 2008 Prospective study of alcohol consumption and metabolic syndrome. Am J Clin Nutr 87:1455-1463 (Pubitemid 351679790)
18. Appel LJ, Moore TJ, Obarzanek E, Vollmer WM, Svetkey LP, Sacks FM, Bray GA, Vogt TM, Cutler JA, Windhauser MM, Lin PH, Karanja N 1997 A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N Engl JMed 336:1117-1124
19. Berglund G, Elmstähl S, Janzon L, Larsson SA 1993 The Malmo Diet and Cancer Study. Design and feasibility. J Intern Med 233:45-51
20. Persson M, Hedblad B, Nelson JJ, Berglund G 2007 Elevated Lp- PLA2 levels add prognostic information to the metabolic syndrome on incidence of cardiovascular events among middle-aged nondiabetic subjects. Arterioscler Thromb Vasc Biol 27:1411-1416 (Pubitemid 46823453)
21. Fenske W, Störk S, Blechschmidt A, Maier SG, Morgenthaler NG, Allolio B 2009 Copeptin in the differential diagnosis of hyponatremia. J Clin Endocrinol Metab 94:123-129
22. 2002 Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106:3143-3421
23. Taylor HL, Jacobs Jr DR, Schucker B, Knudsen J, Leon AS, Debacker G 1978 A questionnaire for the assessment of leisure time physical activities. J Chronic Dis 31:741-755 (Pubitemid 9140316)
24. Wirfält E, Mattisson I, Johansson U, Gullberg B, Wallström P, Berglund G 2002 A methodological report from the Malmo Diet and Cancer study: development and evaluation of altered routines in dietary data processing. Nutr J 1:3
25. Riboli E, Elmstahl S, Saracci R, Gullberg B, Lindgarde F 1997 The Malmo Food Study: validity of two dietary assessment methods for measuring nutrient intake. Int J Epidemiol 26(Suppl 1):S161-S173 (Pubitemid 27129700)
26. Willett W 1998 Nutritional epidemiology. Monographs in epidemiology and biostatistics. New York: Oxford University Press
27. O'Doherty Jensen K, Holm L 1999 Preferences, quantities and concerns: socio-cultural perspectives on the gendered consumption of foods. Eur J Clin Nutr 53:351-359 (Pubitemid 29243429)
28. Hebert JR, Ma Y, Clemow L, Ockene IS, Saperia G, Stanek 3rd EJ, Merriam PA, Ockene JK 1997 Gender differences in social desirability and social approval bias in dietary self-report. Am J Epidemiol 146:1046-1055 (Pubitemid 28030422)
29. Rosvall M, Ostergren PO, Hedblad B, Isacsson SO, Janzon L, Berglund G 2000 Occupational status, educational level, and the prevalence of carotid atherosclerosis in a general population sample of middle-aged Swedish men and women: results from the Malmo Diet and Cancer Study. Am J Epidemiol 152:334-346 (Pubitemid 30626727)
30. Voors AA, von Haehling S, Anker SD, Hillege HL, Struck J, Hartmann O, Bergmann A, Squire I, van Veldhuisen DJ, Dickstein K 2009 C-terminal provasopressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: results from the OPTIMAAL study. Eur Heart J 30:1187-1194
31. Mellbin LG, Rydén L, Brismar K, Morgenthaler NG, Ohrvik J, Catrina SB 2010 Copeptin, IGFBP-1, and cardiovascular prognosis in patients with type 2 diabetes and acute myocardial infarction: a report from the DIGAMI 2 trial. Diabetes Care 33:1604-1606
32. Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS, Orlandi C 2006 Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 355:2099-2112 (Pubitemid 44749318)
33. Gheorghiade M, Konstam MA, Burnett Jr JC, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C 2007 Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA 297:1332-1343 (Pubitemid 46513234)
34. Abraham NG, Brunner EJ, Eriksson JW, Robertson RP 2007 Metabolic syndrome: psychosocial, neuroendocrine, and classical risk factors in type 2 diabetes. Ann NY Acad Sci 1113:256-275 (Pubitemid 350015014)
35. Antoni FA 1993 Vasopressinergic control of pituitary adrenocorticotropin secretion comes of age. Front Neuroendocrinol 14:76-122 (Pubitemid 23210952)
36. Rabadan-Diehl C, Aguilera G 1998 Glucocorticoids increase vasopressin V1b receptor coupling to phospholipase C. Endocrinology 139:3220-3226 (Pubitemid 28512352)
37. Aoyagi T, Birumachi J, Hiroyama M, Fujiwara Y, Sanbe A, Yamauchi J, Tanoue A 2007 Alteration of glucose homeostasis in V1a vasopressin receptor-deficient mice. Endocrinology 148:2075-2084 (Pubitemid 46997065)